SCHEMBL91447

SCHEMBL91447

Cc1cnc2c(c1)OCCN2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 2/20 0.54
ALDH1A1 P00352 2/20 0.46
GAA P10253 2/20 0.46
HSD17B10 Q99714 2/20 0.46
MAPT P10636 1/20 0.46
ALOX5AP P20292 13/20 0.42
FEN1 P39748 13/20 0.42
ADRA2A P08913 1/20 0.35
ADRA2C P18825 1/20 0.35
ADRA1D P25100 1/20 0.35
ADRA1A P35348 1/20 0.35
ADRA1B P35368 1/20 0.35
KDM4E B2RXH2 1/20 0.34
GLA P06280 1/20 0.34
HPGD P15428 1/20 0.34
CASP1 P29466 1/20 0.34
CASP7 P55210 1/20 0.34
ATM Q13315 1/20 0.34
RET P07949 1/20 0.34
IMPDH2 P12268 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30657929 1.00 GRM5 (0.54) GRM5ALDH1A1GAAHSD17B10MAPT
SCHEMBL21201805 0.90 GRM5 (0.44) GRM5ALDH1A1GAAHSD17B10MAPT
SCHEMBL17430662 0.81 GRM5 (0.36) GRM5ALDH1A1GAAHSD17B10MAPT
SCHEMBL12462535 0.79 GRM5 (0.54) GRM5ALDH1A1GAAHSD17B10MAPT
SCHEMBL13114366 0.79 GRM5 (0.54) GRM5ALDH1A1GAAHSD17B10MAPT
SCHEMBL18307148 0.79 GRM5 (0.54) GRM5ALDH1A1GAAHSD17B10MAPT
SCHEMBL858890 0.79 GRM5 (0.54) GRM5ALDH1A1GAAHSD17B10MAPT
SCHEMBL12019744 0.78 GRM5 (0.50) GRM5ALDH1A1GAAHSD17B10MAPT
SCHEMBL84582 0.78 GRM5 (0.50) GRM5ALDH1A1GAAHSD17B10MAPT
SCHEMBL12020144 0.78 GRM5 (0.60) GRM5ALDH1A1GAAHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4522280-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2025-03-19 EP disclosed
US-20250066354-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-02-27 US disclosed
US-12139487-B2 Compounds and uses thereof FOGHORN THERAPEUTICS INC. (US) 2024-11-12 US disclosed
WO-2023220219-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2023-11-16 WO disclosed
US-20230365560-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-11-16 US disclosed
US-20230365560-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-11-16 US disclosed
US-20230365560-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-11-16 US disclosed
WO-2023220219-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2023-11-16 WO disclosed
US-20230192717-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY CASE WESTERN RESERVE UNIVERSITY 2023-06-22 US disclosed
WO-2023030478-A1 PYRIDOLACTAM DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF 浙江海正药业股份有限公司 2023-03-09 WO disclosed
WO-2010077947-A1 PHTHALAZINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2010-07-08 WO disclosed
WO-2010077686-A1 ISOINDOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2010-07-08 WO disclosed
WO-2010056549-A1 PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2010-05-20 WO disclosed
WO-2010037127-A1 CHROMENONE ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2010-04-01 WO disclosed
WO-2010037129-A1 QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS INC. (US) 2010-04-01 WO disclosed
WO-2010026771-A1 NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF, AND BACTERICIDAL AGENT FOR AGRICULTURAL OR HORTICULTURAL APPLICATIONS 日本曹達株式会社 (JP) 2010-03-11 WO disclosed
WO-2010019606-A1 BENZOXAZOLES, BENZTHIAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2010-02-18 WO disclosed
US-20100003246-A1 Novel heterocyclic compounds and uses therof NOVARTIS AG (CH) 2010-01-07 US disclosed
WO-2009112677-A2 BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-09-17 WO disclosed
US-7485724-B2 2,4-pyrimidinediamine compounds and their uses RIGEL PHARMACEUTICALS, INC. (US) 2009-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066354-A1 COMPOUNDS AND USES THEREOF BRCA1, VHL, TFEB GRM5 4409/4885ALDH1A1 888/4885GAA 18/4885
US-20230192717-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY HPGD, GCDH, HPGDS GRM5 1364/4885ALDH1A1 126/4885GAA 420/4885
US-12139487-B2 Compounds and uses thereof BRCA1, VHL, TFEB GRM5 4409/4885ALDH1A1 888/4885GAA 18/4885
US-20230365560-A1 COMPOUNDS AND USES THEREOF BRCA1, VHL, TFEB GRM5 4409/4885ALDH1A1 888/4885GAA 18/4885
US-20100003246-A1 Novel heterocyclic compounds and uses therof BRAF, ARAF, KRAS GRM5 3996/4885ALDH1A1 3257/4885GAA 2653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.